Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- NPO J-CLEAR Says Diovan Data Manipulated Possibly Outside of Endpoint Committee
July 24, 2013
- JPMA Calls on TPP Member States to Make Drug Pricing Process Transparent
July 22, 2013
- FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
- JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
- Pharmaceutical-Related Companies Should Report Business Results to CSIMC: JMARI Working Paper
July 11, 2013
- Product Names Changed for 10% of New Drugs after NDA Filings: OPIR Survey
July 8, 2013
- JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
- JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs
July 5, 2013
- JPA to Bolster Strategies for Key Issues thru Policy Study Committee: Pres. Kodama
July 2, 2013
- JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
- Generic Share Reaches 25.8% by Volume, 10.5% by Price in FY2012: JGA
July 1, 2013
- JGA to Establish New Membership Category to Encourage Non-Member Companies to Provide Information through Its Website
June 27, 2013
- JGA Concerned about TPP Talks, Hopes Japan Will Adopt US Rules Favorable to Generic Makers
June 24, 2013
- JPMA Weighs Scheme to Allow Use of Clinical Research Evidence for Drug Applications
June 21, 2013
- Generic-Only Distributors Total 485, Only 17% Are Member Companies: Generic Distributor Association Survey
June 13, 2013
- FPMAJ Subcommittee Floats New Pricing Rule to Replace Cost Calculation Method
June 12, 2013
- FPMAJ Subcommittee Says NHI Prices of Essential Drugs Should Be Maintained; Stable Supply System for Disasters Envisioned as Requirement
June 11, 2013
- 30% of Newly Listed Drugs in FY2012 Developed at Request of Govt: FPMAJ Survey
June 10, 2013
- FPMAJ Committee Appoints Eisai’s Tsuchiya, Takeda’s Aoyagi as Vice Chairman
June 7, 2013
- Consumers Need to Take Caution with Online OTC Drug Sales: Keizai Doyukai Chairman Hasegawa
June 7, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…